These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 21073667)

  • 1. Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.
    Reny JL; Bonvini RF; Bonvini JM; Roffi M; Fontana P
    Cardiovasc Ther; 2012 Feb; 30(1):e41-50. PubMed ID: 21073667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
    Cross J
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S48-53. PubMed ID: 19355809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
    Tentzeris I; Jarai R; Farhan S; Brozovic I; Smetana P; Geppert A; Wojta J; Siller-Matula J; Huber K
    Thromb Haemost; 2010 Dec; 104(6):1211-8. PubMed ID: 20941464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.
    Faxon DP
    Catheter Cardiovasc Interv; 2012 Feb; 79(2):181-97. PubMed ID: 21618679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel withdrawal: is there a "rebound" phenomenon?
    Sambu N; Warner T; Curzen N
    Thromb Haemost; 2011 Feb; 105(2):211-20. PubMed ID: 21103667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual antiplatelet drug resistance in patients with acute coronary syndrome.
    Guha S; Sardar P; Guha P; Roy S; Mookerjee S; Chakrabarti P; Deb PK; Chaudhuri U; Deb S; Karmakar R; Dasgupta AK; Lahiri P
    Indian Heart J; 2009; 61(1):68-73. PubMed ID: 19729693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
    Faxon DP
    Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
    Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thienopyridine antiplatelet agents: focus on prasugrel.
    Freeman MK
    Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet options for secondary prevention in acute coronary syndromes.
    Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The state of periprocedural antiplatelet therapy after recent trials.
    Desai NR; Bhatt DL
    JACC Cardiovasc Interv; 2010 Jun; 3(6):571-83. PubMed ID: 20630450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management.
    Cowley MJ; Kuritzky L
    Curr Med Res Opin; 2009 Jun; 25(6):1477-90. PubMed ID: 19419337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
    Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
    Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive pharmacologic therapy in percutaneous coronary intervention: part I antiplatelet therapy.
    Kim SJ; Giugliano RP; Jang IK
    Coron Artery Dis; 2011 Mar; 22(1):100-12. PubMed ID: 20926950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.